Observational studyBritish journal of cancer2026
Faecal haemoglobin-based referral and investigation prioritisation is associated with colorectal cancer-specific survival in symptomatic patients: a retrospective observational study.
Observational study in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundCurrent BSG/ACPGBI and NICE guidance recommends that faecal haemoglobin (f-Hb) ≥10 ug/g measured by faecal immunochemical test (FIT) in symptomatic patients should prompt referral through cancer prioritised diagnostic pathways. However, limited long term CRC outcome data exist. This study compared CRC specific survival (CSS) between patients by f-Hb concentration and referral priority in a large primary care f-Hb prioritised lower GI symptomatic pathway.
methodsRetrospective single health board study of symptomatic patients submitting FIT in primary care, 2019-2022. CRC diagnoses up to 3 years after pathway entry, and CRC deaths (ICD10 18, 19, 20) to end 2024 were recorded from cancer audit and MCN datasets. Patients were grouped by f-Hb concentration and referral priority. Univariable and multivariable Cox regression estimated CSS.
resultOf 126,984 patients, 1453 (1%) were diagnosed with CRC within 3 years of f-Hb result or referral, of which 444 (31%) died due to CRC. At multivariable analysis, referral without FIT (HR 1.42, 95% CI 1.06-1.91), and f-Hb ≥10 ug/g diagnosed outwith CRC prioritised pathways (HR 1.47, 95% CI 1.03-2.10) were associated with worse CSS independent of TNM stage.
conclusionReferral and investigation through cancer prioritised pathways guided by f-Hb concentration is safe in relation to CSS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.